Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | MMP14 | P50281 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7145234 | 0.84 | MMP13 (0.52) | MMP13MMP14CYP3A4TP53POLB | |
| SCHEMBL7139295 | 0.83 | MMP13 (0.50) | MMP13MMP14CYP3A4TP53POLB | |
| SCHEMBL7146719 | 0.81 | MMP13 (0.48) | MMP13MMP14CYP3A4TP53POLB | |
| SCHEMBL7148417 | 0.80 | POLB (0.55) | MMP13MMP14CYP3A4TP53POLB | |
| SCHEMBL7151093 | 0.77 | KDM4E (0.51) | MMP13MMP14CYP3A4TP53POLB | |
| SCHEMBL4815246 | 0.71 | MMP13 (0.50) | MMP13MMP14CYP3A4TP53POLB | |
| SCHEMBL7146299 | 0.71 | POLB (0.47) | TP53POLBLMNAKDM4EMAPT | |
| SCHEMBL941412 | 0.70 | MMP13 (0.55) | MMP13MMP14CYP3A4TP53LMNA | |
| SCHEMBL4812127 | 0.70 | MMP13 (0.58) | MMP13MMP14CYP3A4TP53POLB | |
| SCHEMBL4805311 | 0.70 | TP53 (0.60) | MMP13MMP14CYP3A4TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100548-A1 | Arylpiperazines and their use as metallaproteinase inhibiting agents (mmp) | ASTRAZENECA AB (SE) | 2003-05-29 | — | — | US | disclosed |
| EP-1274697-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001062750-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100548-A1 | Arylpiperazines and their use as metallaproteinase inhibiting agents (mmp) | MMP13, MMP3, MMP11 | MMP13 1/4885MMP14 9/4885CYP3A4 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.